- Home
- REA vs NGEN Comparison
REA vs NGEN Comparison
Compare REA & NGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | REA | NGEN |
|---|---|---|
| Founded | N/A | 2017 |
| Country | | Canada |
| Employees | N/A | 9 |
| Industry | Metal Mining | |
| Sector | Basic Materials | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 232.3M | 197.5M |
| IPO Year | 2026 | N/A |
Fundamental Metrics
Financial Performance| Metric | REA | NGEN |
|---|---|---|
| Price | $10.16 | $1.64 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $18.00 |
| AVG Volume (30 Days) | 119.5K | ★ 782.7K |
| Earning Date | N/A | 04-02-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $10.57 | $1.59 |
| 52 Week High | $17.84 | $5.93 |
Technical Indicators
Market Signals| Indicator | REA | NGEN |
|---|---|---|
| Relative Strength Index (RSI) | 27.43 | 35.21 |
| Support Level | N/A | $1.65 |
| Resistance Level | $12.20 | $2.28 |
| Average True Range (ATR) | 1.03 | 0.12 |
| MACD | -0.07 | 0.01 |
| Stochastic Oscillator | 5.56 | 13.83 |
Price Performance
Historical ComparisonAbout REA Rare Earths Americas Inc. Common Stock
Rare Earths Americas Inc is an exploration stage company focused on advancing projects related to rare earth minerals. Its activities include evaluating mineralization and assessing the characteristics and economic potential of its assets. Its portfolio includes the Shiloh Project in Georgia, United States; the Alpha Project in Bahia, Brazil; and the Constellation Project in Minas Gerais, Brazil. It also holds additional early-stage exploration projects, including the Homer Project in Goiás, Brazil, and the Liberty Peak Project in Georgia, United States. The company has two reportable segments due to their geographical location: United States Mining Operations and Brazil Mining Operations.
About NGEN NervGen Pharma Corp. Common stock
NervGen Pharma Corp is a clinical-stage biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury and other traumatic and neurologic conditions. The Company's principal business activity is the discovery, development and commercialization of neuroreparative therapeutics for spinal cord injury (SCI) and other neurotraumatic and neurologic conditions. NervGen's initial target indication is SCI. The company's pipeline products include NVG-291 and NVG-300.